{"id":"W2908553092","doi":"10.1016/s1474-4422(18)30405-8","title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; School of Public Health, University of California Berkeley; St. Jude Medical; National Institutes of Health; Sunovion; H. Lundbeck A/S; Parkinson Study Group; Kyowa Kirin Pharmaceutical Development; AstraZeneca; International Parkinson and Movement Disorder Society; Acorda Therapeutics; Abbott Laboratories; Śląski Uniwersytet Medyczny; AbbVie; CHDI Foundation; Roche; Novartis; Adamas Pharmaceuticals; ACADIA Pharmaceuticals; Merck; US WorldMeds; National Parkinson Foundation; Pfizer; Michael J. Fox Foundation for Parkinson's Research; American Parkinson Disease Association; Teva Pharmaceutical Industries; Kyowa Hakko Kirin","keywords":"Levodopa; Placebo; Medicine; Parkinson's disease; Clinical endpoint; Inhaler; Inhalation; Physical therapy; Clinical trial; Internal medicine; Anesthesia; Disease; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001317896,0.001799441,0.004049037,0.0004152997,0.0006421182,0.00115,0.001040491,0.003084277,0.006330712],"category_scores_gemma":[0.001799533,0.0007349212,0.002259339,0.0003936857,0.001595611,0.001320136,0.0004167964,0.002928032,0.00144333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007141257,"about_ca_system_score_gemma":0.0009641158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001324248,"about_ca_topic_score_gemma":0.00217168,"domain_scores_codex":[0.9993586,0.0003114594,0.00004831618,0.0001255089,0.00005041511,0.000105736],"domain_scores_gemma":[0.9990091,0.0003417956,0.0001641395,0.00006741041,0.00007341852,0.0003441387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9890746,0.002224494,0.0002636058,0.0003577175,0.0003606736,0.00003544859,0.0000305634,0.00009231002,0.001732841,0.00003842499,0.0003094242,0.00547986],"study_design_scores_gemma":[0.9429985,0.05448493,0.001617885,0.00002060844,0.000202946,0.00002798546,0.0000173187,0.0001831741,0.000175263,0.00007406325,0.0001829396,0.00001445266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898468,0.003556517,0.0004012474,0.000475033,0.0004544145,0.002197857,0.0009253988,0.0001242169,0.002018539],"genre_scores_gemma":[0.9917765,0.001716559,0.0006219095,0.0006985668,0.0004261631,0.001755827,0.0009003087,0.0000234817,0.002080678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006330712,"threshold_uncertainty_score":0.02117831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01526237623651743,"score_gpt":0.2623306480630693,"score_spread":0.2470682718265519,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}